Katharina Bolsewig
Overview
Explore the profile of Katharina Bolsewig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bolsewig K, Willemse E, Sanchez-Juan P, Rabano A, Martinez M, Doecke J, et al.
Nat Commun
. 2025 Jan;
16(1):1139.
PMID: 39881147
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we...
2.
Bolsewig K, van Unnik A, Blujdea E, Gonzalez M, Ashton N, Aarsland D, et al.
Neurology
. 2024 Jun;
102(12):e209418.
PMID: 38830138
Background And Objectives: Plasma β-amyloid-1-42/1-40 (Aβ42/40), phosphorylated-tau (P-tau), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) have been widely examined in Alzheimer disease (AD), but little is known about...
3.
Bolsewig K, Blok H, Willemse E, Zwaaftink R, Kooistra M, Smets E, et al.
Alzheimers Dement (Amst)
. 2024 Feb;
16(1):e12549.
PMID: 38371360
Introduction: We aimed to evaluate informal caregivers' attitudes toward undergoing and future implementation of blood-based biomarkers (BBBM) testing for Alzheimer's disease (AD). Methods: We explored caregivers' perspectives, by combining an...
4.
Teunissen C, Kimble L, Bayoumy S, Bolsewig K, Burtscher F, Coppens S, et al.
Mol Cell Proteomics
. 2023 Aug;
22(10):100629.
PMID: 37557955
Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or...
5.
Hok-A-Hin Y, Bolsewig K, Ruiters D, Lleo A, Alcolea D, Lemstra A, et al.
Alzheimers Dement (Amst)
. 2023 Jul;
15(3):e12456.
PMID: 37502019
Introduction: Our previous antibody-based cerebrospinal fluid (CSF) proteomics study showed that Thimet oligopeptidase (THOP1), an amyloid beta (Aβ) neuropeptidase, was increased in mild cognitive impairment with amyloid pathology (MCI-Aβ+) and...
6.
Bolsewig K, Hok-A-Hin Y, Sepe F, Boonkamp L, Jacobs D, Bellomo G, et al.
J Alzheimers Dis
. 2022 Sep;
90(1):363-380.
PMID: 36120776
Background: The differential diagnosis of frontotemporal dementia (FTD) is still a challenging task due to its symptomatic overlap with other neurological diseases and the lack of biofluid-based biomarkers. Objective: To...
7.
Mavrina E, Kimble L, Waury K, Gogishvili D, de San Jose N, Das S, et al.
Front Neurol
. 2022 Jul;
13:890638.
PMID: 35903119
Proteomics studies have shown differential expression of numerous proteins in dementias but have rarely led to novel biomarker tests for clinical use. The Marie Curie MIRIADE project is designed to...